A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections

Delaney E. Hart,1 Jason C. Gallagher,2 Laura A. Puzniak,3 and Elizabeth B. Hirsch1; for the C/T Alliance to deliver Real-world Evidence (CARE)

1University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA, 2Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA, and 3Merck & Co., Inc., Kenilworth, New Jersey, USA

Background. Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa.

Methods. This was a 14-center retrospective cohort study of adult immunocompromised inpatients treated for ≥24 hours with C/T for MDR P. aeruginosa infections. Patients were defined as immunocompromised if they had a history of previous solid organ transplant (SOT), disease that increased susceptibility to infection, or received immunosuppressive therapies. The primary outcomes were all-cause 30-day mortality and clinical cure.

Results. Sixty-nine patients were included; 84% received immunosuppressive agents, 68% had a history of SOT, and 29% had diseases increasing susceptibility to infection. The mean patient age was 57 ± 14 years, and the median (interquartile range) patient Acute Physiology and Chronic Health Evaluation II and Charlson Comorbidity Index scores were 18 (13) and 5 (4), respectively, with 46% receiving intensive care unit care at C/T initiation. The most frequent infection sources were respiratory (56%) and wound (11%). All-cause 30-day mortality was 19% (n = 13), with clinical cure achieved in 47 (68%) patients. Clinical cure was numerically higher (75% vs 30%) in pneumonia patients who received 3-g pneumonia regimens vs 1.5-g regimens.

Conclusions. Of 69 immunocompromised patients treated with C/T for MDR P. aeruginosa, clinical cure was achieved in 68% and mortality was 19%, consistent with other reports on a cross-section of patient populations. C/T represents a promising agent for treatment of P. aeruginosa resistant to traditional antipseudomonal agents in this high-risk population.

Keywords. ceftolozane/tazobactam; immunocompromised; multidrug-resistant; P. aeruginosa; pneumonia.

Ceftolozane/tazobactam (C/T) was approved for use in the United States in 2014 [1]. C/T is approved for treatment of complicated urinary tract infections (cUTIs) including pyelonephritis using a 1.5-g-based regimen and for complicated intra-abdominal infections in combination with metronidazole. In 2019, C/T was also approved for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) at an increased 3-g-based regimen [1–3]. C/T has demonstrated activity against multidrug-resistant (MDR) Pseudomonas aeruginosa and ESBL-producing Enterobacterales via numerous in vitro studies [4–7].

Complex patient populations are often excluded from phase 3 clinical trials to ensure homogeneity of the patient population.
better understand the place in therapy for this agent among this high-risk patient group.

**METHODS**

**Study Design and Data Collection**

This was a multicenter, retrospective cohort study of adult (≥18 years) immunocompromised in patients treated for MDR *P. aeruginosa* from any infection source between March 2015 and July 2018. Data were collected from 14 centers across the United States. Inclusion criteria included treatment with C/T for ≥24 hours, a positive index culture for MDR *P. aeruginosa*, and immunocompromised status at the time of treatment. Patients were considered immunocompromised if they met any of the following criteria: previous solid organ transplant (SOT) recipient; having a disease that increased susceptibility to infection (leukemia, lymphoma, diffuse metastatic cancer); or receipt of therapy that increased susceptibility to infection including immunosuppressive agents, chemotherapy, radiation, steroids at doses capable of immunosuppression (≥10 mg of prednisone for ≥1 month before hospitalization or >15 mg/kg/d of hydrocortisone or ≥3 mg/kg/d of methylprednisolone for >5 days). Lack of C/T susceptibility data for *P. aeruginosa* index culture(s) was not an exclusion criterion.

Clinical and microbiologic data for this study were entered into a standardized data collection form using REDCap, a secure, web-based application designed to support data capture for research studies, providing (1) an intuitive interface for validated data entry, (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for importing data from external sources. Data collected included baseline demographics, infection type and source, antimicrobial use and duration, and clinical outcomes. The clinical decisions regarding infection treatment and antimicrobial selection were at the discretion of the attending physicians at each respective hospital. Dosing of C/T was selected by the ordering provider at each individual site. Pneumonia-dosed C/T was defined as the Food and Drug Administration (FDA)–approved dosing for HABP/VABP at 3 g intravenously every 8 hours or renally adjusted per package insert (further referred to as “pneumonia dosing/dosed” within the manuscript). Severity of illness was assessed by capturing Acute Physiology and Chronic Health Evaluation (APACHE) II scores, and degree of comorbid illness was assessed using the Charlson comorbidity index (CCI). These scores were calculated based on patient laboratory values on day 1 of suspected infection.

**Patient Consent Statement**

The study was approved at each center by the designated institutional review board. Due to the retrospective study design, the requirement for signed patient consent was waived.

**Definitions**

Index cultures were defined as the first culture positive for MDR *P. aeruginosa* for which C/T therapy was prescribed; *P. aeruginosa* isolates were characterized as MDR if nonsusceptible to ≥3 classes of antipseudomonal agents [18]. The index events were defined as infection or suspected infection/event for which C/T therapy was prescribed. In patients with polymicrobial infections, the first negative culture was defined as clearance of the MDR *P. aeruginosa* for which C/T was initiated. Infection was defined as per the US Centers for Disease Control and Prevention criteria for each source as assessed by individual investigators.

**Statistical Analysis**

Baseline patient characteristics and treatment parameters were compared between treatment groups using the Student *t* test and Kruskal-Wallis test for continuous variables and the Fisher exact test for categorical variables. Classification and regression tree (CART) analysis was used to identify the 30-day mortality split in APACHE II scores to assess which patients may be at a greater risk for mortality. Statistical significance was set at a level of *P* < .05. Statistical analyses were performed using Systat, version 13.0 (Systat Software, Inc., San Jose, CA, USA).

**Outcomes**

The primary outcomes were all-cause 30-day mortality and clinical cure. Clinical cure was assessed in patients who received continuous C/T therapy for ≥72 hours and was defined as no escalation of additional antipseudomonal antibiotic therapy and improved signs and symptoms from baseline to end of therapy, including defervescence and discharge notations indicating stability of infection. In patients with pneumonia, primary outcomes were compared between those who received approved pneumonia (3-g-based regimen) and nonpneumonia dosing. Secondary outcomes included length of C/T therapy and total length of hospital stay. Outcomes were assessed by site investigators and confirmed by at least 1 other investigator (E.B.H., D.E.H., or J.C.G.).

**RESULTS**

**Clinical Characteristics**

A total of 69 patients were included; 58 (84%) had received immunosuppressive agents, 47 (66%) had a history of SOT, and 20 (29%) had diseases that increased susceptibility to infection including leukemia (9%), lymphoma (4%), and diffuse metastatic cancer (13%) (Table 1). The mean patient age was 57 ± 14 years, and common comorbidities included chronic pulmonary disease (46%), chronic kidney disease (41%), and diabetes (25%). The median (interquartile range [IQR]) patient APACHE II and Charlson Comorbidity Index scores were 18 (13) and 5 (4), respectively, with 32 (46%) receiving intensive care unit (ICU) care at C/T initiation. The
most frequent infection sources were respiratory (57%) and wound (12%). Four patients had multiple infection sources: 1 had a CNS, bone/joint, and wound infection; 1 had pneumonia and wound infection; 2 had concurrent CNS and bone/joint infections.

### Treatment Characteristics

Overall, 36% of patients had a polymicrobial culture, with 45% of patients receiving combination antimicrobial therapy. The most commonly used concurrent antibiotics were aminoglycosides in 15 patients (48% of concurrent antibiotics), followed by fluoroquinolones in 9 patients (29%), polymyxins in 7 patients (23%), and beta-lactams in 2 patients (6%). Of the 39 patients with pneumonia, 28 (71.8%) received 3-g pneumonia dosing, 10 (25.6%) received 1.5-g (nonpneumonia) dosing, and 1 patient had incomplete dosing data.

### Outcomes

All-cause 30-day mortality among all patients was 19% (13/69), with clinical cure achieved in 68% (47/69) of patients (Table 2). Clinical cure and all-cause 30-day mortality rates varied by infection source, with the highest rates of clinical cure in patients with UTI (100%; 6/6) and bloodstream infections (100%; 6/6) and the lowest all-cause 30-day mortality rates in patients with central nervous system and bone/joint infections (both 0%) (Figure 1). In patients with pneumonia, clinical cure was 75% (21/28) in the 3-g pneumonia dosing group vs 30% (3/10) in the nonpneumonia dosing group, and 30-day mortality was 18% (5/28) in those who received the pneumonia-dose C/T vs 30% (3/10) in those who did not. The mean length of C/T therapy was 13 ± 10.8 days, and the median (IQR) length of hospital stay was 38 (55) days. CART analysis identified the 30-day mortality split at APACHE II score >25 (76% vs 24%; P = 0.002).

### DISCUSSION

This 14-center study aimed to evaluate real-world treatment patterns and clinical outcomes of immunocompromised patients treated with C/T for multidrug-resistant *P. aeruginosa* infections. As a majority of current clinical data exclude immunocompromised patients or these patients make up a small subset of the studied patient population, it is pertinent to describe outcomes in this high-risk group. Patients in our cohort were characterized as immunocompromised for a variety of conditions. A majority of patients were taking immunosuppressive agents (84%), a subset had a history of SOT (68%), and a smaller subset of patients had diseases conferring susceptibility to infection such as active malignancies (29%). In addition to an immunocompromised status of all included patients, many were considered critically ill, demonstrated by a median APACHE II score of 18, with 46% of patients receiving ICU-level care

### Table 1. Baseline Characteristics of the Patients

| Characteristic                      | Total (n = 69)     |
|-------------------------------------|-------------------|
| Age, mean ± SD, y                   | 57 ± 14           |
| In ICU on day 1, No. (%)            | 32 (48)           |
| APACHE II score, median (IQR)       | 18 (13)           |
| Charlson comorbidity index, median (IQR) | 5 (4)  |
| Immunocompromised type, a No. (%)   | 58 (84)           |
| Receiving immunosuppressive agents  | 47 (68)           |
| Solid organ transplant recipient    | 20 (29)           |
| Immuno-compromising disease state, b | 20 (29)           |
| Chronic pulmonary disease           | 32 (46)           |
| Chronic kidney disease              | 28 (41)           |
| Diabetes                            | 17 (25)           |
| Myocardial infarction               | 10 (14)           |
| Heart failure                       | 10 (14)           |
| Peptic ulcer disease                | 9 (13)            |
| Liver dysfunction                   | 9 (13)            |
| Peripheral vascular disease         | 8 (12)            |
| Cerebrovascular disease             | 5 (7)             |
| Metastatic solid tumor              | 5 (7)             |
| Cystic fibrosis                     | 4 (6)             |
| Hemiplegia/paraplegia               | 2 (3)             |
| Infection source, c No. (%)         |                   |
| Pneumonia                           | 39 (57)           |
| Wound                               | 8 (12)            |
| Intra-abdominal                      | 6 (10)            |
| Primary bloodstream infection       | 6 (10)            |
| Urinary tract                       | 6 (10)            |
| Bone/joint                          | 4 (6)             |
| Central nervous system              | 3 (4)             |
| Concurrent antibiotics, No. (%)     | 31 (45)           |
| Aminoglycoside                      | 15 (48)           |
| Fluoroquinolone                     | 9 (29)            |
| Polymyxin                           | 7 (23)            |
| Beta-lactam                         | 2 (6)             |

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; IQR, interquartile range.

*Patients could have multiple reasons for immunocompromised classification.

*Two patients with unspecified disease characterized as sufficiently advanced to suppress resistance to infection, for example, leukemia, lymphoma, diffuse metastatic cancer.

*Patients could have multiple sources of infection.

### Table 2. Clinical Outcomes

| Outcome                                           | Total (n = 69), No. (%) |
|---------------------------------------------------|-------------------------|
| Clinical cure, all infection sources (n = 69)      | 47 (68)                 |
| Pneumonia, receiving pneumonia dosing (n = 28)     | 21 (75)                 |
| Pneumonia, receiving nonpneumonia dosing (n = 10)  | 3 (30)                  |
| 30-d all-cause mortality, all infection sources (n = 69), No. (%) | 13 (19)     |
| Pneumonia, receiving pneumonia dosing (n = 28)     | 5 (18)                  |
| Pneumonia, receiving nonpneumonia dosing (n = 10)  | 3 (30)                  |
| Length of C/T therapy, mean ± SD, d               | 13 ± 11                 |
| Length of hospital stay, median (IQR), d           | 38 (54)                 |

Abbreviations: C/T, ceftolozane/tazobactam; IQR, interquartile range.
upon C/T initiation. The CART analysis identifying the 30-day mortality split at APACHE II score >25 demonstrates that the most critically ill patients with a high APACHE II score were at greatest risk for mortality. Furthermore, these patients had prolonged hospital stays, as demonstrated by a median hospital length of stay of 38 days, although many factors can confound hospital length of stay in immunocompromised patients.

In the present study of 69 immunocompromised patients, morbidity and clinical cure rates were similar to previous, larger studies conducted within nonimmunocompromised patient populations. Patients receiving 1.5-g C/T dosing plus metronidazole in the ASPECT-cIAI trial had a clinical cure rate of 76.9% in patients receiving C/T, and patients treated with the 3-g C/T dose in the phase 3 ASPECT-NP clinical trial had a 28-day all-cause mortality rate of 24.0% and clinical cure rate of 54% [3, 19]. In addition to the phase 3 trials evaluating C/T, 1 of the largest studies evaluating use of C/T specifically for MDR P. aeruginosa reported clinical success in 73.7% of patients and 30-day mortality in 19% of patients [20]. This study included 205 patients, with a median age (IQR) of 60 (48–70) years and the most frequent infection source being pneumonia (59%). The median CCI (IQR) was 4 (3–6), and the median APACHE II score (IQR) was 19 (11–24), which was similar to the comorbidity and severity of illness of patients in the present study. Of the 205 patients, 35 (17.1%) had a history of organ transplantation and 33 (16.1%) had a history of cancer, although outcomes were not reported specific to disease states. A recent observational cohort study of C/T use for MDR or XDR P. aeruginosa evaluated 58 patients, noting a 63.8% clinical cure rate and 27.6% 30-day mortality; however, only 7 (12%) of the included patients were reported to be immunosuppressed [13, 21]. In comparison to these larger studies, immunocompromised individuals in the present study had very similar clinical success (68%) and all-cause 30-day mortality (19%) rates.

When evaluating clinical outcomes by infection source in this cohort, clinical cure was achieved most often in patients with UTI, bloodstream infections, and intra-abdominal infections. Thirty-day all-cause mortality rates ranged from 0% to 25% overall and were lowest in patients with bone/joint infections and CNS infections; however, these groups were very small, making the data difficult to extrapolate. A primary source of pneumonia encompassed slightly over half (n = 39; 56%) of the patient cohort. Clinical cure was achieved in only 62% of these patients; however, upon analysis of clinical cure stratified by FDA-approved 3-g pneumonia dosing of C/T, clinical cure was numerically higher in those who received the appropriate pneumonia dose (75% vs 30%), and 30-day mortality was numerically lower (18% vs 30%) in the pneumonia patients receiving pneumonia dosing. This higher 3-g dose/indication was approved in 2019 while data from this retrospective cohort date back to 2015, so it is reasonable that the higher 3-g pneumonia dosing was not universally used off-indication. While this cohort is small, these results demonstrate the importance of utilizing the FDA-approved dosing of 3 g for patients with pneumonia.

Other smaller studies examining the outcomes of C/T use exclusively among immunocompromised patients have consisted
mainly of case reports or small case series [10, 12]. One retrospective review of 21 patients treated with C/T for MDR P. aeruginosa included a large subset of immunocompromised patients, with 9 (43%) characterized as transplant recipients [14]. This study reported a 30-day all-cause mortality rate of 10% and a clinical success rate of 71%. A recent review of 6 adult patients with hematologic malignancies or hematopoietic cell transplant recipients treated with C/T monotherapy for MDR P. aeruginosa demonstrated a 100% 30-day survival and 71.4% clinical cure rate. Sources of infection in these patients included pneumonia (n = 3), undefined primary source (n = 3), and soft tissue infection (n = 1) [10].

To our knowledge, this is the largest cohort study examining outcomes in an immunocompromised patient population; however, it does have several limitations. Our study is limited by the relatively small sample size as well as the retrospective nature of data collection. Documented history of immunocompromising conditions, such as SOT (n = 47), was used to categorize patients having increased susceptibility to infection. However, it was not known in all cases how recent a patient’s SOT or cancer diagnosis was or what level of immunosuppressive therapy they were being treated with at the time of the index culture. Specifications regarding source control of various infections and reasons for patients not meeting the study definition of clinical cure were not collected and therefore not assessed. Additionally, there was no control group with which to compare C/T outcomes with alternative antibiotics. However, the study was robust in the aspect that patient data were collected across 14 medical centers in various geographical areas of the United States and therefore represents a real-world approach to treatment and outcomes in this complicated patient population. Though a large proportion of patients received concurrent antimicrobials, an assessment of whether they possessed in vitro activity against the P. aeruginosa index isolate was not conducted. Further investigation could be warranted to assess the role of potential combination therapy and outcomes related to MDR P. aeruginosa infections. Among the 31 patients receiving C/T plus concurrent antibiotics, the largest proportion were treated with aminoglycosides, which are known to cause nephrotoxicity [13]. In light of the potent in vitro activity of C/T against MDR P. aeruginosa, use of C/T as a means to avoid use of more toxic broad-spectrum antibiotics could contribute to improved stewardship goals such as decreased antibiotic resistance and/or decreased potential for adverse effects in light of the improved safety profile of beta-lactams [7].

CONCLUSIONS

In this cohort of 69 immunocompromised patients from 14 US centers treated with C/T, we found clinical cure (68%) and mortality (19%) rates similar to those reported in randomized clinical trials and other real-world studies. Our data help to support the conclusion that C/T appears to be a safe and effective therapy for treatment of MDR P. aeruginosa infections in immunocompromised patients. Clinical cure and mortality differences seen in patients with pneumonia stratified by dosing scheme underscore the need to ensure that the approved 3-g dose is being used in patients with pneumonia. Larger controlled studies are warranted to further validate these outcomes.

Acknowledgments

We thank the members of the C/T Alliance to deliver Real-world Evidence (CARE) for assistance with data collection. These members include: Aiman Bandali, Kirthana R. Beulac, Tiffany E. Bias, Kenneth Biason, Christopher M. Bland, Kimberly Boeser, Saira Chaudhry, Kimberly C. Claeys, Ashley L. Cublson, Brandon Dionne, Deepali Dixit, Claudine El-Beyrouty, Abdulrahman Elabor, Elizabeth Gancher, Yi Guo, Nicole Harrington, Emily L. Heil, Jon Hiles, Bruce M. Jones, Madeline A. King, Xiaoning Lu, Monica V. Mahoney, Dorothy McCoy, Erin K. McCreary, Esther Molnar, Ashley Piche, Janet K. Raddatz, Lynette Richards, Nidhi Saraiya, Michael J. Satlin, Jin Suh, Abinash Virk, Nikunj M. Vyas, Daohai Yu.

We also thank Dr. Meghan Jeffers and Dr. David van Duin for their critical review and comments on this manuscript.

Financial support. This work was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Potential conflicts of interest. J.C.G. has received grant funding from Merck and consulting honoraria from Astellas, Merck, Qpex, scPharmaceuticals, Shionogi, and Sero Therapeutics. D.E.H. has no conflicts to declare. E.B.H. has received research funding from Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and advisory honoraria from Nabriva Therapeutics and Merck. L.A.P. is an employee of MSD, who may own stock and/or hold stock options in the company.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Prior presentation. A portion of this study was presented at the 2019 IDWeek meeting, Washington, DC, USA, October 2–6, 2019.

References

1. Ceftolozane/tazobactam (ZERBAXA®) [prescribing information]. Merck Sharp & Dohme Corp.; 2019.
2. Giancola SE, Mahoney MV, Bias TE, Hirsch EB. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections. Ther Clin Risk Manag 2016; 12:777–97.
3. Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2019; 19:1299–311.
4. Shortridge D, Castanheira M, Pfaffer MA, Flamm RK. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother 2017; 61: AAC0465-17.
5. Pfaffer MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother 2017; 72:1386–95.
6. Livermore DM, Mushat S, Meunier D, et al; BSAC Resistance Surveillance Standing Committee. Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae. Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother 2017; 72:2278–89.
7. Hirsch EB, Brigan HV, Zucchi PC, et al. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacteriales clinical isolates from U.S. medical centres. J Glob Antimicrob Resist 2020; 22:689–94.
8. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257–72.

9. Trecarichi EM, Tumbarello M. Antimicrobial-resistant gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis 2014; 27:200–10.

10. Hakki M, Lewis JS 2nd. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients. Infection 2018; 46:431–4.

11. Gerlach AT, Goff D, Bazan JA. Ceftolozane/tazobactam for the treatment of osteomyelitis due to multidrug-resistant Pseudomonas aeruginosa. Infect Dis Clin Practice 2019; 27:339–42.

12. Saraca LM, Di Giuli C, Sicari F, et al. Use of ceftolozane-tazobactam in patient with severe medium chronic purulent otitis by XDR Pseudomonas aeruginosa. Case Rep Infect Dis 2019; 2019:2683701.

13. Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2020; 71:304–10.

14. Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 2017; 65:110–20.

15. Aitken SL, Kontoyiannis DP, DePombo AM, et al. Use of ceftolozane/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient. Pediatr Infect Dis J 2016; 35:1040–2.

16. Obeid JS, McGraw CA, Minor BL, et al. Procurement of shared data instruments for Research Electronic Data Capture (REDCap). J Biomed Inform 2013; 46:259–65.

17. Harris PA, Taylor R, Thielke R, et al. Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–81.

18. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–81.

19. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462–71.

20. Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis 2018; 5:ofy280.

21. Díaz-Cañestro M, Periañez L, Mulet X, et al. Ceftolozane/tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: experience from the Balearic Islands. Eur J Clin Microbiol Infect Dis 2018; 37:2191–200.